News Release

Metal-free graphene quantum dots show promise for highly efficient tumor therapy

Peer-Reviewed Publication

Chinese Academy of Sciences Headquarters

Schematic illustration showing the role of GQDs


Schematic illustration showing the role of GQDs, derived from erythrocyte membranes, as peroxidase--mimic enzyme for tumor catalytic therapy

view more 

Credit: FHIPS

A research group led by Prof. WANG Hui from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences has introduced a metal-free nanozyme based on graphene quantum dots (GQDs) for highly efficient tumor chemodynamic therapy (CDT).

The study was published in Matter.

GQDs represent a promising and cost-effective means of addressing the toxicity concerns associated with metal-based nanozymes in tumor CDT. However, the limited catalytic activity of GQDs has posed significant challenges for their clinical application, particularly under challenging catalytic conditions.

"The obtained GQDs, which are made from red blood cell membranes, are highly effective in treating tumors with few side effects," said LIU Hongji, a member of the research team. "One of the advantages is that they are metal-free. In addition, they function as excellent peroxidase-like biocatalysts."

To enhance the catalytic performance of the GQD-based nanocatalytic adjuvant, the researchers rationally designed GQDs using a diatomic doping strategy. The synergistic electron effect of introducing nitrogen and phosphorus into GQDs can generate highly localized states near the Fermi level, thus enabling efficient enzymatic activity compared to single heteroatom doping.

The obtained GQDs, derived from erythrocyte membranes, have been shown to possess impressive peroxidase-mimicking activity. As a result, the GQDs are highly effective at inducing apoptosis and ferroptosis of cancer cells in vitro. They also selectively target tumors, with a tumor inhibition rate as high as 77.71% for intravenous injection and 93.22% for intratumoral injection, with no off-target side effects.

This drug-free, target-specific, and biologically benign nanozyme has great potential as a potent biocatalyst for use in safe cancer treatment.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.